Featuring interviews with Drs Julie M Vose, Jesus F San-Miguel, Pierre Fenaux and Sonali M Smith. (Text and Audio Content)
ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CME credit is no longer available for this issue
CREDIT DESIGNATION STATEMENT
CME credit is no longer available for this issue
HOW TO USE THIS CME ACTIVITY
CME credit is no longer available for this issue
This CME activity contains both audio and print components. The participant should listen to the audio MP3s and read the text portion. The text portion of this activity contains edited comments, clinical trial schemas, graphics and references that supplement the audio MP3s, as well as links to relevant full-text articles, abstracts, trial information and other web resources.
CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr Vose — Paid Research: Allos Therapeutics, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Celgene Corporation, Exelixis Inc, Genentech BioOncology, Genzyme Corporation, GlaxoSmithKline, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, Pharmacyclics Inc, S*BIO Pte Ltd, US Biotest Inc. Dr San-Miguel — Advisory Committee: Celgene Corporation, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation. Dr Fenaux — Consulting Agreements: Celgene Corporation, GlaxoSmithKline, Novartis Pharmaceuticals Corporation; Paid Research: Celgene Corporation. Dr Smith — Advisory Committee: Allos Therapeutics, Bristol-Myers Squibb Company, Celgene Corporation, Cephalon Inc, Genentech BioOncology, GlaxoSmithKline, Pfizer Inc, Spectrum Pharmaceuticals Inc; Consulting Agreements: Allos Therapeutics, Celgene Corporation, Cephalon Inc, Genentech BioOncology, GlaxoSmithKline; Speakers Bureau: Biogen Idec, Celgene Corporation, Genentech BioOncology.
EDITOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Allos Therapeutics, Amgen Inc, Astellas Pharma Global Development Inc, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Cephalon Inc, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Genentech BioOncology, Genomic Health Inc, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Lilly USA LLC, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Myriad Genetics Inc, Novartis Pharmaceuticals Corporation, OSI Oncology, Sanofi and Seattle Genetics.
RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.
This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
This activity is supported by educational grants from Allos Therapeutics, Celgene Corporation, Cephalon Inc, Genentech BioOncology/Biogen Idec, Millennium: The Takeda Oncology Company, Onyx Pharmaceuticals Inc, Sanofi and Seattle Genetics.
Hardware/Software Requirements:
An Internet connection that is at least 28.8 Kbps
A monitor set to 1280 x 1024 pixels or more
Internet Explorer 6.x or newer, Firefox 2.x or newer, or Safari 2.x or newer
Macromedia Flash plug-in 6.0 or greater
Adobe Acrobat Reader
(Optional) Sound card and speakers for audio
Last review date: October 2011
Expiration date: October 2012
Featuring interviews with Drs Julie M Vose, Jesus F San-Miguel, Pierre Fenaux and Sonali M Smith. (Text and Audio Content)